| Parameters |
ABI <0.6
N=36 |
ABI 0.6-0.9
N=71 |
ABI >0.9
N=97 |
| Age, y |
73 ± 13* |
71 ± 11 |
71 ± 14 |
| M/F |
23/13 |
44/27 |
71/26 |
| NYHA class II/III |
21/15 * |
48/23 |
75/22 |
| Ethiology |
|
|
|
| CAD |
27 (75) |
49 (69) |
57 (59) |
| Hypertension |
4 (11) |
14 (20) |
28 (29) |
| Valvular disease |
4 (11) |
6 (8) |
12 (12) |
| Dilated cardiomiopaty |
1 (3) |
2 (3) |
- |
| BMI ( kg/m2) |
29 ± 8 |
28 ± 4 |
27 ± 5 |
| Resting heart rate, bpm |
88 ± 7 |
76 ± 7 |
74 ± 8 |
| Systolic BP, mmHg |
108 ± 19 |
107 ± 21 |
113 ± 17 |
| Diastolic BP, mmHg |
82 ± 10 |
80 ± 14 |
80 ± 12 |
| Echocardiography |
|
|
|
| LVEF, % |
27 ± 7* |
34 ± 6 |
37 ± 9 |
| LVDD, mm |
63.1 ± 11 |
62.6 ± 8 |
58 ± 7 |
| E/A ratio |
1.4 ± 0.7 |
1.4 ± 0.8 |
1.6 ± 0.8 |
| E deceleration time |
171 ± 23 |
180 ± 17 |
181 ± 14 |
| Comorbidities |
|
|
|
| Hypertension |
21 (58) |
43 (60) |
58 (59) |
| Diabetes |
16 (44) * |
25 (35) |
31 (28) |
| Dislipidemia |
22 (61 ) |
42 (59) |
59 (51) |
| COPD |
14 (38) |
27 (39) |
33 (34) |
| Atrial fibrillation |
15 (41 ) * |
18 (25) |
22 (23) |
| History of smoke |
24 (66) |
37 (52) |
47(48) |
| Laboratory |
|
|
|
| Creatinine, mg/dl |
1.7 ± 0.2 * |
1.4 ± 0.2 |
1.3 ± 0.2 |
| Hemoglobin, g/dl |
10.4 ±2 |
11.1 ± 4 |
11.7 ± 2 |
| NT-proBNP |
823.6 ±31* |
432.3 ± 47 |
357 ± 38 |
| Therapy |
|
|
|
| Beta-blockers |
29 (80) |
64 (90) |
81 (84) |
| ACE-i/ARBs |
32 (88) |
62 (87) |
88 (91) |
| Diuretics |
26 (72) |
58 (81) |
64 (66) |
| Digoxin |
11(30) |
20 (28) |
34 (35) |
*= p<0.05 ABI <0.6 vs. ABI >0.9 |
